CI Financial ( TSX: CIX:CA) ( OTCPK:CIXXF) received an interim order from the Ontario Superior Court of Justice that ...
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...
Shareholders who have questions or need assistance in voting should contact Laurel Hill Advisory Group by telephone at 1-877-452-7184 (North American Toll Free) or 1-416-304-0211 (Outside North ...
CI Financial receives an interim court order concerning the transaction under which CI shares will be acquired by an affiliate of Mubadala Capital.
GlobalData on MSN1d
Light Horse emerges with $62m and Novartis partnership worth up to $1bnLight Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...
Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...
“Tenvie was purpose-built to apply deep biological and chemical insights to address critical disease pathways,” said Paul L. Berns, Managing Director at ARCH Venture Partners and Executive Chair of ...
On Wednesday, New York-headquartered Focus Financial Partners announced plans to make Cardinal Point, which it acquired in ...
The Holdco shares would then be sold to funds managed by Mubadala Capital instead of a direct sale of CI shares (TSX:CIX:CA). Under that plan, the Holdco shares would be sold for the same total ...
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback